SCHEMBL10139880

SCHEMBL10139880

COc1cccc(NC(=O)N2CCc3[nH]c4ncc(Cl)cc4c3C2)c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.56
MAPT P10636 3/20 0.56
KMT2A Q03164 3/20 0.56
ALOX15 P16050 2/20 0.56
MAPK1 P28482 2/20 0.56
GAA P10253 1/20 0.56
ALOX12 P18054 1/20 0.56
CASP1 P29466 1/20 0.56
CASP7 P55210 1/20 0.56
NPSR1 Q6W5P4 1/20 0.56
NPC1 O15118 2/20 0.54
RAB9A P51151 2/20 0.54
CYP1A2 P05177 1/20 0.52
CYP3A4 P08684 1/20 0.52
CYP2D6 P10635 1/20 0.52
CYP2C9 P11712 1/20 0.52
CYP2C19 P33261 1/20 0.52
MCL1 Q07820 1/20 0.52
HTT P42858 2/20 0.50
BAZ2B Q9UIF8 2/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10139863 0.90 MAPT (0.56) MEN1MAPTKMT2AALOX15MAPK1
SCHEMBL10139888 0.89 MEN1 (0.57) MEN1MAPTKMT2AALOX15MAPK1
SCHEMBL18106977 0.86 LIMK2 (0.43) MEN1MAPTKMT2AALOX15MAPK1
SCHEMBL10139855 0.85 CDK4 (0.52) MEN1MAPTKMT2AALOX15MAPK1
SCHEMBL10139886 0.85 MAPT (0.77) MEN1MAPTKMT2AALOX15MAPK1
Hydrochloric Acid SCHEMBL406799 0.85 CDK4 (0.51) MEN1MAPTKMT2AALOX15MAPK1
SCHEMBL10139873 0.84 MEN1 (0.69) MEN1MAPTKMT2AALOX15MAPK1
SCHEMBL9316614 0.83 MEN1 (0.51) MEN1MAPTKMT2AALOX15MAPK1
SCHEMBL10139856 0.81 CFTR (0.51) MEN1MAPTKMT2AALOX15MAPK1
Hydrochloric Acid SCHEMBL408487 0.80 CFTR (0.51) MEN1MAPTKMT2AALOX15MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2367822-B1 TRICYCLIC AZAINDOLES MERCK PATENT GMBH (DE) 2016-10-05 EP disclosed
US-8853391-B2 Tricyclic azaindoles MERCK PATENT GMBH (DE) 2014-10-07 US disclosed
US-8853391-B2 Tricyclic azaindoles MERCK PATENT GMBH (DE) 2014-10-07 US disclosed
US-20120022060-A1 Tricyclic Azaindoles MERCK PATENT GMBH (DE) 2012-01-26 US disclosed
US-20120022060-A1 Tricyclic Azaindoles MERCK PATENT GMBH (DE) 2012-01-26 US disclosed
WO-2010080253-A1 TRICYCLIC AZAINDOLES MERCK PATENT GMBH (DE) 2010-07-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120022060-A1 Tricyclic Azaindoles AZI2, DCK, PPP2CA MEN1 3463/4885MAPT 2520/4885KMT2A 1887/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.